About Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Industry, Sector and Symbol
Industry MED PRODS
Trailing P/E Ratio-55.9813395534822
Forward P/E Ratio-3.11
Sales & Book Value
Annual Sales$2.67 million
Price / Sales16.53
Price / CashN/A
Book Value($0.19) per share
Price / Book-8.84
Net Income$2.43 million
Return on EquityN/A
Return on Assets-90.03%
Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics Inc (NASDAQ:CAPR) issued its earnings results on Wednesday, March, 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The biotechnology company earned $0.48 million during the quarter, compared to analysts' expectations of $0.63 million. View Capricor Therapeutics' Earnings History.
When will Capricor Therapeutics make its next earnings announcement?
Where is Capricor Therapeutics' stock going? Where will Capricor Therapeutics' stock price be in 2018?
2 brokers have issued twelve-month target prices for Capricor Therapeutics' stock. Their forecasts range from $2.15 to $8.60. On average, they expect Capricor Therapeutics' stock price to reach $5.38 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include Ekso Bionics (EKSO), Alphatec (ATEC), Vermillion (VRML), ConforMIS (CFMS), Biolife Solutions (BLFS), Obalon Therapeutics (OBLN), Edap Tms (EDAP), Invuity (IVTY), Presbia (LENS), Arch Therapeutics (ARTH), BIOLASE (BIOL), Reshape Lifesciences (RSLS), BioSig Technologies (BSGM), PURE Bioscience (PURE), Imprimis Pharmaceuticals (IMMY), Rewalk Robotics (RWLK), Cesca Therapeutics (KOOL) and Microbot Medical (MBOT).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
- Joshua A. Kazam, Director (Age 40)
Has Capricor Therapeutics been receiving favorable news coverage?
Media headlines about CAPR stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Capricor Therapeutics earned a coverage optimism score of 0.23 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 44.50 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Capricor Therapeutics' major shareholders?
Capricor Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Brown Advisory Inc. (4.42%). Company insiders that own Capricor Therapeutics stock include Louis Manzo and Sinai Medical Center Cedars. View Institutional Ownership Trends for Capricor Therapeutics.
Which major investors are buying Capricor Therapeutics stock?
CAPR stock was purchased by a variety of institutional investors in the last quarter, including Brown Advisory Inc.. Company insiders that have bought Capricor Therapeutics stock in the last two years include Louis Manzo and Sinai Medical Center Cedars. View Insider Buying and Selling for Capricor Therapeutics.
How do I buy shares of Capricor Therapeutics?
Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of CAPR stock can currently be purchased for approximately $1.68.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $46.76 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.03) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (CAPR)MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Capricor Therapeutics (NASDAQ:CAPR) Earnings History and Estimates Chart
Capricor Therapeutics (NASDAQ CAPR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/14/2018||Q4 2017||($0.10)||($0.11)||$0.63 million||$0.48 million||View||Listen|
|11/8/2017||Q3 2017||($0.19)||($0.12)||$1.00 million||$0.31 million||View||N/A|
|8/10/2017||Q2 2017||($0.18)||($0.16)||$1.10 million||$1.00 million||View||N/A|
|5/15/2017||Q1 2017||($0.15)||($0.17)||$0.87 million||$0.88 million||View||N/A|
|3/15/2017||Q4 2016||($0.30)||($0.14)||$1.05 million||$0.91 million||View||N/A|
|11/10/2016||Q316||($0.27)||($0.29)||$1.12 million||$0.75 million||View||N/A|
|8/15/2016||Q2||($0.24)||($0.26)||$1.22 million||$1.13 million||View||Listen|
|5/12/2016||Q116||($0.19)||($0.26)||$1.10 million||$1.22 million||View||Listen|
|3/17/2016||Q415||($0.19)||($0.21)||$1.10 million||$1.12 million||View||N/A|
|11/12/2015||Q315||($0.26)||($0.18)||$1.10 million||$1.32 million||View||N/A|
|8/13/2015||Q215||($0.26)||($0.19)||$1.10 million||$1.29 million||View||N/A|
|5/12/2015||Q1 2015||($0.14)||($0.23)||$1.10 million||$1.79 million||View||N/A|
|3/18/2015||Q4 2014||($0.14)||($0.16)||$1.30 million||$1.40 million||View||N/A|
|11/13/2014||Q3 2014||($0.22)||($0.13)||$1.30 million||View||N/A|
|8/14/2014||Q2 2014||($0.13)||$1.04 million||View||N/A|
|5/15/2014||Q1 2014||($0.10)||$1.04 million||View||N/A|
Capricor Therapeutics (NASDAQ:CAPR) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS
Dividend History for Capricor Therapeutics (NASDAQ:CAPR)
No dividend announcements for this company have been tracked by MarketBeat.com
Capricor Therapeutics (NASDAQ CAPR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 9.46%
Capricor Therapeutics (NASDAQ CAPR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/9/2017||Louis Manzo||Director||Buy||10,000||$3.10||$31,000.00||138,384|| |
|5/9/2017||Sinai Medical Center Cedars||Major Shareholder||Buy||1,145,161||$3.10||$3,549,999.10||4,049,959|| |
|9/21/2016||Sinai Medical Center Cedars||Major Shareholder||Buy||312,500||$3.20||$1,000,000.00||2,904,798|| |
|3/16/2016||Anthony Bergmann||VP||Buy||2,030||$2.40||$4,872.00||2,030|| |
|3/16/2016||Karen Krasney||EVP||Buy||4,060||$2.40||$9,744.00||11,156|| |
|3/16/2016||Leland Gershell||CFO||Buy||2,100||$2.40||$5,040.00||2,100|| |
|3/16/2016||Linda Marban||CEO||Buy||10,152||$2.40||$24,364.80|| |
|3/16/2016||Louis J Grasmick||Director||Buy||91,369||$2.40||$219,285.60|| |
|3/16/2016||Sinai Medical Center Cedars||Major Shareholder||Buy||416,666||$2.40||$999,998.40||2,592,298|| |
|8/20/2015||Louis J. Grasmick||Director||Buy||11,900||$4.11||$48,909.00||5,950|| |
|8/19/2015||Eduardo Marban||major shareholder||Buy||18,400||$4.36||$80,224.00||3,173,354|| |
|1/21/2015||Joshua A Kazam||Director||Buy||7,096||$3.52||$24,977.92|| |
|1/21/2015||Sinai Medical Center Cedars||Major Shareholder||Buy||851,546||$3.52||$2,997,441.92|| |
Capricor Therapeutics (NASDAQ CAPR) News Headlines
|Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences - GlobeNewswire (press release)|
globenewswire.com - March 21 at 8:48 AM
|Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences|
finance.yahoo.com - March 21 at 8:48 AM
|Capricor Therapeutics (CAPR) versus Versartis (VSAR) Critical Contrast|
www.americanbankingnews.com - March 16 at 5:22 AM
|Capricor Therapeutics (CAPR) Posts Earnings Results, Misses Estimates By $0.01 EPS|
www.americanbankingnews.com - March 15 at 10:45 AM
|Capricor Therapeutics, Inc. to Host Earnings Call|
finance.yahoo.com - March 14 at 7:07 PM
|Has Capricor Therapeutics Inc (NASDAQ:CAPR) Improved Earnings Growth In Recent Times?|
finance.yahoo.com - March 14 at 7:07 PM
|Earnings Preview For Capricor Therapeutics|
finance.yahoo.com - March 14 at 7:07 PM
|Capricor posts 4Q profit|
finance.yahoo.com - March 14 at 7:07 PM
|Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update|
finance.yahoo.com - March 14 at 7:07 PM
|Capricor Therapeutics (CAPR) Upgraded to "Buy" by Zacks Investment Research|
www.americanbankingnews.com - March 12 at 7:10 PM
|Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on ... - GlobeNewswire (press release)|
globenewswire.com - March 9 at 8:20 AM
|Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14|
finance.yahoo.com - March 8 at 6:44 PM
|Capricor Therapeutics (CAPR) Cut to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - March 7 at 6:57 PM
|Capricor Therapeutics (CAPR) Lifted to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 6 at 7:00 PM
|Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Tuesday|
www.americanbankingnews.com - March 6 at 2:32 AM
|Brown Advisory Inc. Buys New Stake in Capricor Therapeutics Inc (CAPR)|
www.americanbankingnews.com - March 2 at 5:10 AM
|Capricor to Host Key Opinion Leader Lunch on March 9 - GlobeNewswire (press release)|
globenewswire.com - March 1 at 8:15 AM
|Capricor to Host Key Opinion Leader Lunch on March 9|
finance.yahoo.com - February 28 at 8:17 AM
|Report: Developing Opportunities within Tupperware Brands, Eaton Vance, Marcus & Millichap, Lockheed Martin, Coherus BioSciences, and Capricor Therapeutics — Future Expectations, Projections Moving into 2018|
finance.yahoo.com - February 23 at 8:21 AM
|New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy|
finance.yahoo.com - February 22 at 5:38 PM
|Capricor Therapeutics (CAPR) Lowered to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - February 14 at 7:12 PM
|Capricor Therapeutics (CAPR) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - February 13 at 7:00 PM
|Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy|
finance.yahoo.com - February 12 at 9:44 AM
|Pre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more...)|
www.streetinsider.com - February 5 at 3:40 PM
|Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy|
finance.yahoo.com - February 5 at 3:40 PM
|BRIEF-Capricor Therapeutics Says FDA Has Granted CAP-1002 RMAT Designation|
www.reuters.com - February 5 at 9:34 AM
|Zacks Investment Research Downgrades Capricor Therapeutics (CAPR) to Hold|
www.americanbankingnews.com - February 2 at 6:42 PM
|Who Are Capricor Therapeutics Inc’s (NASDAQ:CAPR) Major Shareholders?|
finance.yahoo.com - January 30 at 3:43 PM
|Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwright|
www.americanbankingnews.com - January 26 at 11:48 PM
| Capricor Therapeutics Inc (CAPR) Receives Consensus Rating of "Strong Buy" from Analysts|
www.americanbankingnews.com - January 24 at 5:42 PM
|Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies|
finance.yahoo.com - January 16 at 8:58 AM
| Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of "Strong Buy" by Brokerages|
www.americanbankingnews.com - December 30 at 7:46 AM
|Capricor Therapeutics (CAPR) versus Trevena (TRVN) Head to Head Review|
www.americanbankingnews.com - December 29 at 9:30 AM
|Market Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst Ratings|
finance.yahoo.com - December 18 at 8:58 AM
|ETFs with exposure to Capricor Therapeutics, Inc. : December 14, 2017|
finance.yahoo.com - December 14 at 5:23 PM
|Capricor Therapeutics Announces Issuance of Key US Patent on Exosome Technology - PR Newswire (press release)|
www.prnewswire.com - December 13 at 5:01 PM
|BRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome Technology|
www.reuters.com - December 13 at 9:05 AM
|Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology|
finance.yahoo.com - December 13 at 9:05 AM
|BRIEF-Capricor & California Institute For Regenerative Medicine Entered Into Amendment 3 To CIRM Notice Loan Award|
www.reuters.com - December 12 at 5:11 PM
|CAPRICOR THERAPEUTICS, INC. - StreetInsider.com|
www.streetinsider.com - December 12 at 10:30 AM
|Stock Review for Biotech's Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and ... - PR Newswire (press release)|
www.prnewswire.com - December 11 at 5:01 PM
|Stock Review for Biotech's Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and BioDelivery Sciences|
www.bizjournals.com - December 11 at 9:31 AM
|Capricor Therapeutics (CAPR) versus Its Rivals Critical Contrast|
www.americanbankingnews.com - December 8 at 7:46 PM
|Zacks: Analysts Set $6.50 Target Price for Capricor Therapeutics Inc (CAPR)|
www.americanbankingnews.com - December 8 at 3:48 AM
|How Does Capricor Therapeutics Inc’s (CAPR) EPS Growth Stack Up Against Industry Performance?|
finance.yahoo.com - December 6 at 5:56 PM
|Critical Contrast: Capricor Therapeutics (CAPR) & Its Rivals|
www.americanbankingnews.com - December 5 at 3:32 AM
|Active-Investors: Wired News - FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy|
www.finanznachrichten.de - December 1 at 4:15 PM
|Wired News – FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy|
finance.yahoo.com - December 1 at 4:15 PM
|ETFs with exposure to Capricor Therapeutics, Inc. : November 30, 2017|
finance.yahoo.com - November 30 at 4:49 PM
| Capricor Therapeutics, Inc. (CAPR) Given $6.50 Consensus Target Price by Analysts|
www.americanbankingnews.com - November 30 at 2:18 PM
Capricor Therapeutics (NASDAQ:CAPR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Capricor Therapeutics (NASDAQ:CAPR) Income Statement, Balance Sheet and Cash Flow Statement
Capricor Therapeutics (NASDAQ CAPR) Stock Chart for Wednesday, March, 21, 2018